Natera’s Signatera wins Japan PMDA approval as companion diagnostic in muscle-invasive bladder cancer

PUBT · 1d ago
Natera’s Signatera wins Japan PMDA approval as companion diagnostic in muscle-invasive bladder cancer
  • Natera won PMDA clearance in Japan for Signatera as a companion diagnostic in muscle-invasive bladder cancer.
  • Authorization supports MRD-guided adjuvant use of Roche’s Tecentriq (atezolizumab) in eligible post-surgery patients.
  • Commercial launch targeted for 1H 2027, pending final reimbursement and pricing decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609220800BIZWIRE_USPR_____20260922_BW775835) on September 22, 2026, and is solely responsible for the information contained therein.